Abstract
The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Current Drug Targets
Title: Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Volume: 4 Issue: 2
Author(s): C. Chandra Kumar
Affiliation:
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Abstract: The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Export Options
About this article
Cite this article as:
Kumar Chandra C., Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis, Current Drug Targets 2003; 4 (2) . https://dx.doi.org/10.2174/1389450033346830
DOI https://dx.doi.org/10.2174/1389450033346830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Telomeres and their Role in Aging and Longevity
Current Vascular Pharmacology Steroid Receptor-Associated Immunophilins: Candidates for Diverse Drug-Targeting Approaches in Disease
Current Molecular Pharmacology The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Current Drug Targets Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Simultaneous Modeling of Antimycobacterial Activities and ADMET Profiles: A Chemoinformatic Approach to Medicinal Chemistry
Current Topics in Medicinal Chemistry Substitution at Phenyl Rings of Chalcone and Schiff Base Moieties Accounts for their Antiproliferative Activity
Anti-Cancer Agents in Medicinal Chemistry A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Custom DNA-Binding Proteins and Artificial Transcription Factors
Current Topics in Medicinal Chemistry Taxotere Chemosensitivity Evaluation in Rat Breast Tumor by Multimodal Imaging: Quantitative Measurement by Fusion of MRI, PET Imaging with MALDI and Histology
Recent Patents on Medical Imaging Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Cognitive Impacts of Estrogen Treatment in Androgen-Deprived Males: What Needs to be Resolved
Current Neuropharmacology Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design Combination of Salinomycin and AZD3463 Reveals Synergistic Effect on Reducing the Viability of T98G Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Current Drug Targets Working Hypothesis: Elimination of Cancer Stem Cells in Solid Tumors by Immuno-Gene Therapy Using Cancer Vaccines and Created-Inhibitory RNA
Current Cancer Therapy Reviews Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention
Current Topics in Medicinal Chemistry Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design